Last reviewed 2026-05-22 · How we verify

Skincerity

The University of Texas Health Science Center, Houston · Phase 1 active Small molecule ✓ Verified May 2026

Skincerity is a Small molecule drug developed by The University of Texas Health Science Center, Houston. It is currently in Phase 1 development.

Skincerity is a topical treatment that has been studied in clinical trials for conditions such as Tuberous Sclerosis, Neurofibromatoses, Angiofibroma, and Neurofibroma. It is used in combination with sirolimus/rapamycin, a medication that has been shown to alleviate cutaneous manifestations of these conditions.

Likelihood of approval

9.6% vs 9.6% industry baseline

If approved by FDA: likely 2033–2036

Steps remaining: Phase 2 → Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 1 → approval rate +9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2033–2036	—
EMA	EU	2034–2037	+0.7 yr
MHRA	GB	2034–2037	+0.7 yr
Health Canada	CA	2034–2038	+0.9 yr
TGA	AU	2034–2038	+1.2 yr
PMDA	JP	2034–2038	+1.5 yr
NMPA	CN	2035–2039	+2.3 yr
MFDS	KR	2034–2038	+1.4 yr
CDSCO	IN	2034–2039	+1.8 yr
ANVISA	BR	2035–2039	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	Skincerity
Sponsor	The University of Texas Health Science Center, Houston
Modality	Small molecule
Therapeutic area	Dermatology
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Topical Rapamycin Therapy to Alleviate Cutaneous Manifestations of Tuberous Sclerosis Complex (TSC) and Neurofibromatosis I (NF1) (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Skincerity CI brief — competitive landscape report
Skincerity updates RSS · CI watch RSS
The University of Texas Health Science Center, Houston portfolio CI

Frequently asked questions about Skincerity

What is Skincerity?

Skincerity is a Small molecule drug developed by The University of Texas Health Science Center, Houston.

Who makes Skincerity?

Skincerity is developed by The University of Texas Health Science Center, Houston (see full The University of Texas Health Science Center, Houston pipeline at /company/the-university-of-texas-health-science-center-houston).

What development phase is Skincerity in?

Skincerity is in Phase 1.

Manufacturer: The University of Texas Health Science Center, Houston — full pipeline
Therapeutic area: All drugs in Dermatology

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing